Portfolio of Immune Checkpoint Inhibitor Stocks
Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:
- AstraZeneca (AZN) - durvalumab Imfinzi
- Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
- Merck (MRK) - pembrolizumab Keytruda
- Roche Holding (RHHBY) - atezolizumab TECENTRIQ
| 4 Checkpoint Inhibitor Stocks | ||
|---|---|---|
Name | Symbol | Recent Prices |
| AstraZeneca | AZN | |
| Bristol-Myers Squibb | BMY | |
| Merck | MRK | |
| Roche Holding AG | RHHBY | |
| Price charts from Alpha Vantage as of most recent close. | ||
Portfolio Values
To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.The 3 stocks included in the portfolio computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.
The current value of a $10,000 investment is $16,420. The percent return is 64.20%. The annualized return is 10.43%.
Portfolio Value Chart for Last 100 Daily Closes
Values of User-Selected Sample Portfolios: Discover the Most and Least Profitable Sample Portfolios
Related Portfolios
Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks